ProStrakan Secures Offer From Japan's Kyowa Hakko, But Analysts Say Too Low
This article was originally published in PharmAsia News
Executive SummaryThree months after putting itself up for sale, U.K.-based specialty pharma firm ProStrakan Group PLC on Feb. 21 announced a cash offer from Japan's Kyowa Hakko Kirin Co. Ltd. The 130 pence-per-share deal values the company at about £292 million ($475 million)
You may also be interested in...
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).